KIYATEC’s clinically validated, predictive 3D ex vivo assays characterize response to I/O, targeted, and chemo therapies. Data from our proprietary platforms span most solid tumors including ovarian, GBM, breast, & rare. Our services cover all phases of preclinical development thru clinical trials.